Agree Realty Corporation (ADC)
| Market Cap | 8.20B +3.4% |
| Revenue (ttm) | 779.62M +18.2% |
| Net Income | 217.01M +21.0% |
| EPS | 1.86 +10.5% |
| Shares Out | 124.54M |
| PE Ratio | 35.43 |
| Forward PE | 33.48 |
| Dividend | $3.20 (4.86%) |
| Ex-Dividend Date | Sep 30, 2026 |
| Volume | 1,623,992 |
| Open | 65.21 |
| Previous Close | 65.03 |
| Day's Range | 64.98 - 66.16 |
| 52-Week Range | 64.98 - 82.08 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 82.94 (+25.9%) |
| Earnings Date | Oct 20, 2026 |
About ADC
Agree Realty Corporation is a publicly traded real estate investment trust. The Firm is Rethinking Retail through the acquisition and development of properties net leased to industry-leading, omni-channel retail tenants. As of June 30, 2026, the Company owned and operated a portfolio of 2,825 properties, located in all 50 states and containing approximately 59.6 million square feet of gross leasable area. Agree Realty Corporation was incorporated in 1971 and is based in Royal Oak, United States.
Financial Performance
In 2025, Agree Realty's revenue was $718.40 million, an increase of 16.42% compared to the previous year's $617.10 million. Earnings were $196.47 million, an increase of 8.38%.
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ADC stock is "Buy." The 12-month stock price target is $82.94, which is an increase of 25.90% from the latest price.
News
Agree Realty assumed with a Buy at Truist
Truist analyst Linda Tsai assumed coverage of Agree Realty (ADC) with a Buy rating and price target of $75, down from $82. The firm assumed coverage of the net lease…
Agree Realty Announces Third Quarter 2026 Earnings Release Date and Conference Call Information
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its third quarter 2026 operating results after the market closes on Tuesday...
Agree Realty price target lowered to $85 from $87 at Evercore ISI
Evercore ISI lowered the firm’s price target on Agree Realty (ADC) to $85 from $87 and keeps an Outperform rating on the shares. Adjustments to REIT valuations “reflect a careful…
Agree Realty price target lowered to $81.50 from $84 at Stifel
Stifel lowered the firm’s price target on Agree Realty (ADC) to $81.50 from $84 and keeps a Buy rating on the shares after the company announced it had priced $400M…
Agree Realty Announces Pricing of $400 Million of 5.650% Senior Unsecured Notes Due 2036
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its operating partnership, Agree Limited Partnership (the “Operating Partnership”), priced ...
Agree Realty price target lowered to $72 from $80 at Mizuho
Mizuho analyst Haendel St. Juste lowered the firm’s price target on Agree Realty (ADC) to $72 from $80 and keeps a Neutral rating on the shares. The firm says the…
Agree Realty Publishes Sixth Annual Sustainability Report
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the "Company") today announced the release of its 2025 Sustainability Report. The report highlights the Company's environmental...
Agree Realty Declares Monthly Common and Preferred Dividends
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividen...
Agree Realty price target raised to $93 from $92 at BofA
BofA raised the firm’s price target on Agree Realty (ADC) to $93 from $92 and keeps a Buy rating on the shares. The firm adjusted several net lease REIT targets…
Agree Realty Earnings Call Transcript: Q2 2026
Record Q2 investment and portfolio growth drove raised full-year AFFO and investment guidance, with strong year-over-year earnings and dividend increases. Operational efficiency gains and robust liquidity position support continued expansion and risk management.
Agree Realty Earnings release: Q2 2026
Agree Realty released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
Agree Realty Quarterly report: Q2 2026
Agree Realty has published its Q2 2026 quarterly earnings report on July 31, 2026.
Agree Realty Slides: Q2 2026
Agree Realty has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 31, 2026.
Agree Realty price target raised to $83 from $82 at Baird
Baird analyst Wesley Golladay raised the firm’s price target on Agree Realty (ADC) to $83 from $82 and keeps an Outperform rating on the shares. The firm updated its model…
Agree Realty reports Q2 AFFO $1.14, consensus $1.13
Reports Q2 revenue $205.1M, consensus $206.91M.
Agree Realty raises FY26 AFFO view to $4.57-$4.59 from $4.54-$4.58
Consensus $4.56. “We are very pleased with our record performance during the first half of the year, as we posted the most active investment quarter and first half in Company…
Agree Realty Corporation Reports Second Quarter 2026 Results
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended June 30, 2026. All per share amounts included herein are on a dilu...
Agree Realty price target raised to $85 from $84 at Barclays
Barclays raised the firm’s price target on Agree Realty (ADC) to $85 from $84 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the net…
Agree Realty initiated with an Outperform at Huntington
Huntington initiated coverage of Agree Realty (ADC) with an Outperform rating and $84 price target
Agree Realty Announces Second Quarter 2026 Earnings Release Date and Conference Call Information
ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its second quarter 2026 operating results after the market closes on Thursd...
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical...
Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma
AU, Switzerland & PRINCETON, N.J.--(BUSINESS WIRE)--Araris Biotech AG, a company advancing a differentiated pipeline of antibody-drug conjugates (“ADCs”) therapies, and Taiho Oncology, Inc., a company...
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer
Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms PLEASANTON, Calif., June 17, 2026 /PRNewswire/ --...
Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
HONG KONG, June 15, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally dev...